drugset / Trial / NCT02036164

Summary

Data of survival benefit from adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) for locally advanced cervical cancer (LACC) are still limited and inconsistent. We will investigate if ACT has survival benefit over CCRT alone.

Timeline

Start
2014-01
Primary completion
2018-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 5 unknown Intravenous
Subject Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Cisplatin Other / unclassified 40 mg/m2 Intravenous

Indications